Charles River Laboratories International, Inc. (NYSE: CRL)

Quick Facts / Company Snapshot

Company Name: Charles River Laboratories International, Inc.
Establishment Date: 1947
Headquarters: 251 Ballardvale Street, Wilmington, Massachusetts 01887
Chairman, President, and Chief Executive Officer: James C. Foster
Interim Chief Financial Officer: Michael G. Knell
Number of Employees: Approximately 19,700
Total Revenue (2025): $4,015.4 million
Operating Income (2025): $25.2 million
Net Loss (2025): $(142.2) million
Total Assets (2025): $7,135.4 million
Total Liabilities (2025): $3,924.2 million
Total Equity (2025): $3,169.9 million
Net Cash Provided by Operating Activities (2025): $737.6 million
Capital Expenditures (2025): $(219.2) million
RMS Segment Revenue (2025): $846.1 million
DSA Segment Revenue (2025): $2,402.9 million
Manufacturing Solutions Segment Revenue (2025): $766.4 million
Stock Exchange Listing: New York Stock Exchange (Ticker: CRL)
Global Footprint: Over 120 sites in over 20 countries worldwide
Science Professionals with Advanced Degrees: Approximately 2,400

Company overview

Charles River Laboratories International, Inc. operates as a leading, full-service, non-clinical global drug development partner with an overarching mission to create healthier lives. The organisation has systematically built upon its original core competency of laboratory animal medicine and science, specifically research model technologies, to develop an incredibly diverse and deep portfolio of discovery and safety assessment services. These extensive services encompass both Good Laboratory Practice (GLP) and non-GLP environments, rigorously supporting clients from initial target identification completely through the non-clinical development spectrum. Furthermore, the enterprise provides a comprehensive suite of products and services specifically engineered to support its clients’ critical manufacturing and quality control activities.

By utilising this broad portfolio of products and services, the organisation enables its extensive client base to create a substantially more efficient and flexible drug development model. This integrated approach is purposefully designed to reduce clients’ operational costs, enhance their overall productivity and effectiveness, and critically increase their speed to market. The enterprise recognises that the development of new drugs requires a steadily increasing investment of time and capital, noting that various studies and reports estimate that it takes between 10 to 15 years, up to $2.6 billion excluding time costs, and the exploration of between 10,000 and 15,000 drug molecules to produce a single Food and Drug Administration (FDA)-approved drug.

The enterprise leverages its leading portfolio in non-clinical drug research in an efficient and cost-effective manner to aggressively aid clients in bringing their life-saving drugs to market faster.
The organisation’s massive client base includes major global pharmaceutical companies, numerous biotechnology companies, agricultural and industrial chemical firms, life science organisations, veterinary medicine entities, medical device manufacturers, diagnostic providers, and consumer product companies.
The business also serves contract research and contract manufacturing organisations, other commercial entities, leading hospitals, academic institutions, and government agencies all around the world.

In recent years, the organisation has aggressively focused its efforts on improving the fundamental efficiency of its global operations to enhance its ability to support its clients. The enterprise has observed that pharmaceutical and biotechnology clients are increasingly seeking full-service, “one-stop” global partners to whom they can comprehensively outsource more of their drug discovery and development efforts. Management notes estimates indicating that the market for regulated safety assessment services is 60% outsourced or more, while emerging growth areas such as discovery and certain research model services are currently believed to be less outsourced, providing significant runway for future growth.

Currently, the enterprise operates in over 120 sites and in over 20 countries worldwide, excluding certain Insourcing Solutions sites. The organisation’s products and services, supported heavily by its massive global infrastructure and deep scientific expertise, enable clients to successfully overcome many of the complex challenges associated with non-clinical life sciences research. During the 2025 fiscal year, the enterprise generated a massive total revenue of $4.0 billion. As a critical component of its ongoing efforts to manage the business through the current demand environment, management has undertaken a highly comprehensive review of the global footprint. Through these targeted optimisation initiatives, the organisation expects to close or consolidate approximately 12 additional sites over the next two years, principally focused on the DSA and RMS operating segments. These footprint optimisation efforts are projected to enhance the efficiency and economies of scale within the global infrastructure, ultimately leading to a substantially more disciplined operating model.

Business segments

The enterprise evaluates, oversees, and rigorously manages its financial performance and operational execution through three highly distinct reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Discovery and Safety Assessment (DSA)

The Discovery and Safety Assessment (DSA) segment operates as the absolute largest revenue generator for the organisation. It provides a vast array of services that enable clients to comprehensively outsource their innovative drug discovery research, their related non-clinical and clinical bioanalytical activities, and the regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices.

Segment Revenue (2025): $2,402.9 million
Percentage of Total Revenue: 59.8%
Operating Income (2025): $424.6 million
Employee Base: Approximately 11,760 employees, including approximately 1,680 science professionals possessing advanced degrees.

The demand for these critical services is intensely driven by the complex needs of large global pharmaceutical companies where outsourcing may complement internal activities, in addition to mid-size and emerging biotechnology and biopharma pharmaceutical companies. Furthermore, hospitals, academic institutions, contract research organisations, industrial and agrochemical companies, and non-governmental organisations that rely heavily on outsourcing partners heavily fuel this segment. The enterprise proudly stands as the largest provider of outsourced drug discovery, non-clinical development, and regulated safety testing services worldwide. The segment possesses extensive, industry-leading expertise in the discovery of clinical candidates and in the intricate design, execution, and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, vaccines, and biocides. The DSA segment currently provides its discovery and safety assessment services at multiple, highly advanced facilities located across the United States, Canada, and Europe. In 2025, the organisation initiated the strategic integration of its Discovery Services and Safety Assessment businesses into one unified, overarching DSA organisation, leveraging a combined sales force and integrated scientific expertise to facilitate a more seamless client experience.

Research Models and Services (RMS)

Through its Research Models and Services (RMS) segment, the enterprise has provided the absolute foundational tools required for the discovery of new molecules by supplying research models to the global drug development industry since 1947. The organisation continues to fiercely maintain its position as a global leader in the production and commercial sale of the most widely used research models, which includes over 140 different stocks and strains of highly purpose-bred rodents.

Segment Revenue (2025): $846.1 million
Percentage of Total Revenue: 21.1%
Operating Income (2025): $44.6 million
Employee Base: Approximately 4,140 employees, including approximately 190 science professionals with advanced degrees.

The RMS segment also provides a broad variety of related services that are meticulously designed to support clients in the direct use of research models in drug discovery and development. The enterprise maintains multiple massive production centres, including heavily secured barrier rooms and isolator facilities, spanning across three continents: North America, Europe, and Asia. Furthermore, the organisation is a premier provider of high-quality, purpose-bred, large research models to the biomedical research community. The RMS segment additionally houses the highly successful Insourcing Solutions business, which importantly includes the CRADL (Charles River Accelerator and Development Lab) footprint.

Manufacturing Solutions (Manufacturing)

Within the Manufacturing Solutions segment, the enterprise works intimately with its clients and the broader biopharmaceutical industry to rigorously ensure the quality and safe production and release of commercial therapies and products manufactured both by clients and internally for clients.

Segment Revenue (2025): $766.4 million
Percentage of Total Revenue: 19.1%
Operating Loss (2025): $(184.3) million (This loss was heavily driven by a massive $165.0 million goodwill impairment and a $109.0 million intangible asset impairment)
Employee Base: Approximately 2,600 employees, including approximately 350 science professionals with advanced degrees.

The Manufacturing Segment is fundamentally comprised of two highly specialised businesses: Microbial Solutions and Biologics Solutions. The Microbial Solutions products and services business provides critical in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. Conversely, the Biologics Solutions division is comprised of both the Biologics Testing Solutions business—which provides highly specialised testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies—and the contract development and manufacturing products and services (CDMO) business, which provides comprehensive contract development and manufacturing solutions specifically tailored for complex cell and gene therapies.

History and evolution

The enterprise began its groundbreaking operations in 1947 when a young veterinarian purchased one thousand rat cages from a Virginia farm and established a one-man laboratory in Boston, overlooking the Charles River. Since those early days, the organisation has undergone several massive changes to its business structure, evolving into an undisputed titan of the life sciences industry. The modern corporate entity, Charles River Laboratories International, Inc., was formally incorporated in 1994. A monumental milestone was achieved in the year 2000 when the organisation successfully completed its initial public offering, listing its stock on the prestigious New York Stock Exchange under the enduring symbol “CRL”.

In 1952, the Company relocated its headquarters to 60 acres of farmland in Wilmington, Massachusetts, and began the commercial production of pathogen-free rodents utilising the industry’s first barrier-type building.
In 1984, Virus Antibody Free (VAF/Plus) animals were introduced, setting the gold standard for high-quality research models.
In 1999, Jim Foster and the management team successfully bought the Company back from Bausch & Lomb, simultaneously entering the preclinical safety assessment business via the acquisition of Sierra Biomedical.
In 2001, the enterprise rapidly acquired five preclinical safety sites in the U.S., subsequently establishing itself as a market leader in toxicology and pathology through the massive acquisition of Inveresk.

Over the last two decades, the organisation has relentlessly executed a highly disciplined acquisition strategy designed to consolidate the fragmented North American and European environmental and life sciences markets. For example, in 2013, the acquisition of Vital River established the enterprise as the premier provider of research models and associated services within the rapidly emerging Chinese market. More recently, the organisation continued its aggressive expansion by acquiring Explora BioLabs in fiscal 2022, Noveprim in 2023, and certain assets of K.F. (Cambodia) Ltd. in 2026, which was specifically targeted to vertically integrate its non-human primate supply operations.

The enterprise has also heavily focused on adopting and advancing New Approach Methodologies (NAMs). In 2025, the organisation announced the creation of a cross-functional Scientific Advisory Board to guide its strategic focus on NAMs, demonstrating a profound commitment to eventually reducing the reliance on traditional animal models through advanced in silico and in vitro technologies. Additionally, in January 2026, Dr. Namandjé N. Bumpus was appointed as the Senior Vice President, Chief Scientific and Innovation Officer to lead this critical scientific strategy.

Products and services

The enterprise offers a highly diversified, deeply comprehensive suite of scientific products and services meticulously designed to manage pharmaceutical molecules and therapeutics across their entire lifecycle. These service lines generate distinct, highly recurring revenue streams heavily insulated by stringent regulatory oversight.

Research Models

The Research Models business is principally comprised of the commercial production and sale of the most widely used small research models, primarily rats and mice. This forms an essential part of the drug discovery process, as the FDA and foreign regulatory agencies absolutely require that the safety and efficacy of most new drug candidates be rigorously tested on research models prior to human trials.

The enterprise supplies research models to numerous clients globally, including most major pharmaceutical companies, biotechnology firms, contract research organisations, and academic institutions.
The small research models encompass inbred, outbred, and hybrid strains, as well as complex mutant strains, genetically engineered models, and humanised models possessing unique biological features.
The organisation also stands as a premier provider of high-quality, purpose-bred, large research models, notably including non-human primates (NHPs) sourced internally or from rigorously audited and approved global suppliers.

Research Model Services

This division offers a wide variety of highly flexible solutions explicitly designed to support clients in the direct use of research models during basic research and the screening of pre-clinical drug candidates. It includes three primary service offerings: Insourcing Solutions, Genetically Engineered Models and Services (GEMS), and Research Animal Diagnostic Services (RADS).

Insourcing Solutions: The enterprise manages the entire research operations of government entities, academic organisations, and commercial clients, including recruitment, training, and staffing, utilising both the clients’ facilities and the proprietary CRADL (Charles River Accelerator and Development Lab) vivarium spaces.
Genetically Engineered Models and Services (GEMS): The organisation creates, breeds, and heavily maintains custom research models, providing quarantine, health and genetic testing, and germplasm cryopreservation, all supported by a technologically advanced Internet Colony Management (ICM) system.
Research Animal Diagnostic Services (RADS): The enterprise meticulously monitors and analyses the health profiles of clients’ research models by assessing infectious agents and pathology, operating as an industry-leading reference laboratory.

Cell Solutions

The Cell Solutions business provides critical, consenting human donor-derived cellular materials utilised directly in the development and complex production of advanced cell therapies. The business supplies highly controlled, customised primary cells and blood components derived from normal and mobilised peripheral blood and bone marrow, heavily supporting biotechnology companies executing cutting-edge clinical trials.

Discovery Services

The Discovery Services offering provides a massive single source of capabilities for discovering and characterising novel drug candidates prior to preclinical development. Services span from the initial identification and validation of novel targets, low molecular weight small molecule compounds, oligonucleotides, and complex biotherapeutics, completely through to the delivery of preclinical drug candidates.

The enterprise leverages massive capabilities in pharmacokinetics, pharmacology, non-GLP toxicity assays, and highly predictive models.
Offerings include hit identification, hit-to-lead progression, and lead optimisation utilising state-of-the-art techniques such as computer-aided drug design, structural biology, cell painting, and artificial intelligence.

Safety Assessment

The enterprise is a global leader in both non-regulated and regulated GLP outsourced safety assessment services, offering an exhaustive range of studies required for regulatory submission.

Toxicology: Services encompass acute, sub-acute, and chronic studies, genetic toxicology, safety pharmacology, reproductive and developmental toxicology, juvenile toxicology, and complex carcinogenicity bioassays.
Pathology Services: The organisation employs highly trained veterinary anatomic and clinical pathologists who utilise state-of-the-art digital primary and peer review histopathology, cytology, immunohistochemistry, and spatial analysis to determine therapeutic safety and efficacy.
Bioanalysis, Drug Metabolism and Pharmacokinetics: The enterprise provides sophisticated bioanalytical techniques to demonstrate appropriate biological sample stability, the pharmacokinetics of compounds in circulation, and the presence or absence of anti-drug antibodies for complex biologics.

Microbial Solutions

The Microbial Solutions business operates as a highly rapid, efficient testing platform for the vital microbial detection and identification of both sterile and non-sterile applications. This is executed through the Endosafe, Celsis, and Accugenix brands.

Endosafe: Provides globally mandated lot release testing of medical devices and injectable drugs for endotoxin contamination, utilising limulus amebocyte lysate (LAL) from horseshoe crabs, as well as the new animal-free recombinant test, Endosafe Trillium.
Celsis: Provides extremely rapid microbial detection systems utilising adenosine triphosphate bioluminescence technology, allowing clients to detect contamination within 4 to 7 days to make objective product release decisions.
Accugenix: Acts as the premier provider of ISO17025-accredited contract microbial identification services, executing precise species-level identification and strain typing of bacteria and fungi recovered from manufacturing facilities.

Biologics Solutions

This division is comprised of Biologics Testing Services and the CDMO business.

Biologics Testing Services: Provides analytical characterisation, lot release, and safety testing support for chemistry, manufacturing, and controls (CMC), executing vital viral clearance programs according to GLP and cGMP requirements for Phase I, II, and III human clinical studies.
CDMO Services: Operates in three major areas of the high-growth advanced therapy market: cell therapy, viral vector, and plasmid DNA production, providing an integrated solution from process development entirely through to commercial cGMP production.

Brand portfolio

The enterprise manages its vast global operations primarily under its unified, highly recognisable corporate brand identity, while strategically deploying specific product sub-brands that hold immense equity within the quality control and microbial testing sectors.

Charles River Laboratories

The flagship “Charles River” brand serves as the overarching corporate identity and the absolute dominant consumer-facing presence for all discovery, safety assessment, and research model operations globally.

Core Application: Research models, Discovery Services, Safety Assessment, and overall corporate sustainability initiatives.
Strategic Focus: Projecting unparalleled scientific reliability, absolute regulatory compliance, and a profound commitment to accelerating the global drug development process.

Endosafe

Endosafe operates as the premier sub-brand within the Microbial Solutions division, universally recognised as a global market leader in advanced endotoxin testing products and services.

Core Application: FDA-approved next-generation endotoxin testing, including the Endosafe Portable Testing System (PTS), the automated Endosafe-Nexus, and the animal-free Endosafe Trillium recombinant cascade reagent.
Strategic Focus: Providing highly rapid, technologically advanced lot release testing for the global injectable drug and medical device manufacturing industries.

Celsis

The Celsis brand represents the highly innovative suite of rapid microbial detection systems engineered to ensure the safe manufacture of pharmaceutical and consumer products.

Core Application: Celsis Advance II, Celsis Accel, and Celsis Adapt instruments and software.
Strategic Focus: Utilising bioluminescence technology to drastically reduce product hold times, allowing massive pharmaceutical manufacturers to release sterile products to market substantially faster than legacy methods.

Accugenix

Accugenix operates as the industry-leading brand for contract microbial identification services and species-level strain typing.

Core Application: ISO17025-accredited identification services and the in-house Axcess instrument system.
Strategic Focus: Providing absolute certainty and accurate, timely analysis of environmental contaminants recovered from highly sterile biopharmaceutical manufacturing facilities.

Geographical presence

The enterprise operates a vast, intensely localised network of physical assets strategically positioned across key demographic, scientific, and industrial centres throughout North America, Europe, and Asia.

North America (United States and Canada)

The United States serves as the overwhelming core of the enterprise’s operations, hosting the vast majority of its capital-intensive assets, highly specialised laboratory infrastructure, and dedicated employee base.

Asset Concentration: Houses the massive corporate headquarters in Wilmington, Massachusetts. The region contains an extensive network of heavily regulated Safety Assessment facilities, CRADL vivarium spaces, and large-scale CDMO manufacturing plants.
Strategic Focus: Establishing impenetrable, vertically integrated market densities where massive global pharmaceutical companies and emerging biotechs can seamlessly access the entire continuum of the drug development lifecycle.

The domestic market operates under stringent oversight from the FDA, the Environmental Protection Agency, the United States Department of Agriculture (USDA), the Centers for Disease Control and Prevention (CDC), and the US Fish and Wildlife Service (USFWS). The enterprise thrives in this environment by deploying massive capital to ensure absolute compliance, creating a formidable competitive moat.

Europe

The European operations represent a massive, deeply embedded extension of the global footprint, functioning as a seamless continuation of the enterprise’s integrated life sciences model.

Regulatory Environment: Subject to rigorous oversight by the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, and the Health Products Regulatory Authority in Ireland.
Strategic Focus: Dominating the regional safety assessment and microbial solutions markets while actively partnering with global pharmaceutical entities. The region houses highly specialised Biologics Testing facilities in Germany, Ireland, and France.

Asia Pacific and Other Regions

The Asia Pacific region provides critical operational scale and access to massive, emerging healthcare markets and vital research model supply chains.

Strategic Assets: The enterprise operates extensive research model production facilities and Discovery Services outposts in Asia. Historically, China has acted as a critical supply hub for large research models, although this dynamic is currently constrained by geopolitical export restrictions.
Recent Expansion: In January 2026, the enterprise massively bolstered its regional supply chain by acquiring certain assets of K.F. (Cambodia) Ltd., a Cambodia-based provider of non-human primates, explicitly executing a vertical integration strategy to secure its critical NHP supply for the global Safety Assessment business.

Charles River Laboratories International, Inc. (NYSE CRL) Logo

Profit and loss

Financial Metric	2025 ($ thousands)	2024 ($ thousands)
Total Revenue	4,015,382	4,130,551
Cost of revenue (excluding amortization of intangible assets)	2,692,107	2,718,168
Selling, general and administrative	742,912	751,003
Amortization of intangible assets	179,066	138,464
Intangible asset impairment	210,974	–
Goodwill impairment	165,000	215,000
Operating income	25,162	307,916
Interest expense	101,718 (Cash paid)	123,452 (Cash paid)
Net income (loss) attributable to Charles River	(144,338)	19,842

(Note: Data derived from segment combinations and consolidated balance sheet equivalents. Cash paid for interest is utilised as a directional proxy due to formatting constraints. Total revenue and operating income aggregated from segment reporting.)

Balance sheet

Balance Sheet Item	December 27, 2025 ($ thousands)	December 28, 2024 ($ thousands)
Cash and cash equivalents	213,770	194,606
Trade receivables and contract assets, net	708,856	720,915
Inventories	299,103	278,544
Total current assets	1,447,049	1,403,071
Property, plant and equipment, net	1,655,219	1,604,014
Operating lease right-of-use assets, net	361,415	412,490
Goodwill	2,764,253	2,846,608
Intangible assets, net	339,995	723,400
Total assets	7,135,422	7,528,345
Total current liabilities	1,120,315	994,101
Long-term debt, net and finance leases	2,136,360	2,240,205
Operating lease right-of-use liabilities	434,048	483,789
Total liabilities	3,924,228	4,020,267
Total Charles River Laboratories International, Inc. equity	3,164,630	3,461,503
Total equity	3,169,931	3,466,952

Cash flow

Cash Flow Metric	2025 ($ thousands)	2024 ($ thousands)
Net cash provided by operating activities	737,646	734,577
Capital expenditures	(219,152)	(232,967)
Purchases of investments and contributions to venture capital	(20,076)	(52,876)
Net cash used in investing activities	(209,321)	(245,086)
Proceeds from long-term debt and revolving credit facility	1,227,534	1,081,581
Payments on long-term debt, revolving credit, and finance leases	(1,349,317)	(1,493,769)
Purchase of treasury stock	(360,673)	(119,175)
Net cash used in financing activities	(536,726)	(550,927)
Net change in cash, cash equivalents, and restricted cash	10,427	(78,910)

Board of directors and leadership team

The enterprise is governed by an exceptionally experienced executive leadership team dedicated to driving profound profitable growth, executing complex acquisitions, and relentlessly enforcing rigorous environmental compliance and animal welfare protocols.

James C. Foster Role: Chairman, President, and Chief Executive Officer Profile: Joined the enterprise in 1976 as General Counsel. During his monumental tenure, he held various staff and managerial positions before being named Chief Executive Officer and President in 1992, and Chair in 2000. Under his visionary leadership, the organisation transitioned into a publicly traded powerhouse. In January 2026, the Board announced a leadership transition plan; he intends to retire and step down as CEO and Chair effective May 5, 2026.

Birgit Girshick Role: Chief Operating Officer (Incoming CEO) Profile: Joined the enterprise in 1989 and originally held positions of increasing responsibility in the RMS Germany and Avian Vaccine businesses. In November 2021, she was promoted to Chief Operating Officer, assuming massive responsibility for RMS, Microbial Solutions, CDMO, and Global Information Technologies. In January 2026, the Board unanimously appointed her as the next Chief Executive Officer, concurrent with Mr. Foster’s planned retirement in May 2026.

Michael G. Knell Role: Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer Profile: Joined the Company in April 2017 as Corporate Senior Vice President and Chief Accounting Officer. He is responsible for providing strategic guidance to the finance groups, maintaining the Company’s fiscal records, and overseeing the design and operation of internal controls. In October 2025, he was appointed by the Board to act as the interim Chief Financial Officer.

Victoria Creamer Role: Corporate Executive Vice President, Chief People Officer Profile: Joined the enterprise in January 2019. She is responsible for providing the overarching vision, leadership, and execution of the company’s global people, culture, and human resources strategies, managing a diverse workforce of nearly 20,000 employees.

Joseph LaPlume Role: Corporate Executive Vice President, Corporate Development and Strategy Profile: Joined the organisation in 2005 as Senior Corporate Counsel. In his current immense role, he oversees all aspects of strategic planning and corporate development activities across all business segments and geographies, orchestrating the enterprise’s aggressive mergers and acquisitions framework.

Mark Mintz Role: Corporate Executive Vice President, Chief Information Officer & Global Shared Services Profile: Joined the enterprise in February 2021. He is directly responsible for delivering technology, digital transformation, and shared functional services that further enhance the Company’s abilities to achieve its long-term strategic objectives.

Shannon Parisotto Role: Corporate Executive Vice President, Global Discovery and Safety Assessment Profile: Joined the enterprise in 2000. She progressed through numerous finance management positions before being promoted to oversee the entire strategic vision and operational growth of the massive global DSA segment, violently enhancing synergies between the businesses and clients worldwide.

Subsidiaries, associates, joint ventures

The enterprise operates as a massive corporate holding structure, seamlessly executing its highly complex business through an intricate web of consolidated operating subsidiaries and highly strategic investments.

RMS and DSA Operating Subsidiaries: The organisation utilises an extensive network of wholly-owned subsidiaries to operate its vivariums, toxicology laboratories, and pathology centres across North America, Europe, and Asia.
K.F. (Cambodia) Ltd. (Assets): In January 2026, the enterprise aggressively acquired certain assets of this Cambodia-based entity. This strategic integration functions strictly to vertically integrate the supply of non-human primates directly into the DSA supply operations, guaranteeing a secure pipeline of critical research models.
Manufacturing Solutions Entities: Specific corporate entities govern the highly regulated production of Endosafe LAL reagents, Celsis instrumentation, and the complex cGMP manufacturing environments required for the Biologics and CDMO businesses.

Other Investments (Including Minority / Portfolio Holdings)

The enterprise actively leverages its immense capital resources to make highly strategic, tax-advantaged, and venture capital investments outside of its core operational consolidation to secure adjacent scientific capabilities.

Venture Capital and Strategic Equity Investments
- Nature of Investment: Strategic / Venture
- Profile: The enterprise partners with a diverse set of leading venture capital firms around the world primarily investing in life sciences, health care, and therapeutics with an emphasis on early-stage companies. Through these intimate partnerships, the organisation gains immense, early insight into their company and asset portfolios, allowing it to aggressively promote its services. The organisation views these partnerships as vital investments in new and emerging sciences and cutting-edge technologies. During 2025, the enterprise executed purchases and contributions to these venture capital investments totalling $20.1 million.

Physical properties (offices, plants, factories, etc.)

The absolute operational dominance of the enterprise relies upon a staggering physical footprint of highly engineered industrial properties, heavily regulated laboratories, and sprawling logistical hubs.

Corporate Headquarters: Located at 251 Ballardvale Street, Wilmington, Massachusetts.
Global Footprint: The enterprise currently operates in over 120 sites and in over 20 countries worldwide (excluding certain embedded Insourcing Solutions client sites).
Research Model Facilities: Maintains multiple massive production centres, including impenetrable barrier rooms and flexible film isolator facilities, strategically located in 7 countries in close proximity to major global biohubs.
DSA Laboratories: Operates vast toxicology, pathology, and bioanalytical laboratories across the United States, Canada, and Europe, specifically engineered to comply with strict GLP regulations.
Manufacturing Sites: Includes FDA-registered facilities dedicated to the production of Endosafe LAL testing kits, and state-of-the-art cGMP CDMO facilities capable of manufacturing and storing raw materials, drug substance, and drug product suitable for clinical trials and commercial release.

Founders

The enterprise traces its profound operational legacy directly to the visionary leadership of its founder.

Dr. Henry Foster: In 1947, a young veterinarian, Dr. Henry Foster, purchased one thousand rat cages from a Virginia farm and set up a one-man laboratory in Boston, overlooking the Charles River. Recognising the critical regional need for high-quality, standardised laboratory animal models, he personally bred, fed, and delivered the animals to local researchers, laying the absolute foundation for what would become the largest non-clinical contract research organisation in the world.

Parent

Charles River Laboratories International, Inc. functions exclusively as the ultimate parent holding company. It is a corporation organised under the laws of the State of Delaware. All tangible physical operations, specialised laboratory facilities, real estate assets, and complex client contracts are held and executed entirely by its massive network of consolidated operating subsidiaries. The company is publicly traded on the New York Stock Exchange and does not operate under the umbrella of any other corporate entity.

Investments and capital expenditure plans

The organisation executes a highly disciplined, multi-hundred-million-dollar capital allocation strategy meticulously designed to protect its core physical infrastructure, automate its facilities, and aggressively seize high-growth scientific opportunities.

Core Infrastructure Capital Expenditures (2025: $219.2 million): The absolute vast majority of capital is deployed to maintain and upgrade the existing massive network. This includes replacing ageing mechanical systems, expanding complex barrier facilities for research models, and purchasing advanced analytical equipment for the DSA laboratories.
Strategic Acquisitions: The enterprise continually deploys massive capital toward focused acquisitions within its core markets. In January 2026, the organisation deployed capital to acquire certain assets of K.F. (Cambodia) Ltd. to secure its non-human primate supply chain.
Footprint Optimisation: Following a comprehensive strategic review, the enterprise is actively deploying capital and restructuring expenses to close or consolidate approximately 12 sites over the next two years, driving extreme operational efficiency.
Digital Enhancements: The enterprise is relentlessly investing capital into creating digitally native solutions, including the Apollo cloud-based platform, which provides real-time access to scientific data and self-service tools for clients.

Shareholding pattern

The ownership architecture of the enterprise reflects an exceptionally broad base of massive institutional investors, mutual funds, and individual shareholders who deeply value the organisation’s relentless cash flow generation and aggressive capital return programs.

Total Outstanding Shares: 49,227,800 shares of common stock issued and outstanding as of January 24, 2026.
Share Repurchases: Supported by immense free cash flow, the organisation aggressively repurchased $360.7 million of its own treasury stock during the 2025 fiscal year, a massive increase compared to the $119.2 million repurchased in 2024.
Dividends: The enterprise does not currently pay cash dividends, electing instead to violently restrict the supply of available equity through share buybacks and deploy capital towards highly accretive acquisitions.

Future strategy

The overarching strategic roadmap is defined by a relentless commitment to expanding scientific capabilities, utilising the enterprise’s unmatched physical asset network to deliver superior, end-to-end solutions to the global biopharmaceutical sector while ruthlessly defending operating margins.

Comprehensive Strategic Review: In November 2025, the Board announced a massive strategic shift, determining to divest certain non-core assets representing approximately 7% of 2025 revenue. The enterprise will focus entirely on strengthening its leading scientific portfolio within its core markets through strategic acquisitions, partnerships, and internal investments.
Advancing New Approach Methodologies (NAMs): The strategy fundamentally relies on pioneering the future of non-clinical research. The enterprise will aggressively invest in developing, validating, and commercialising NAMs—such as organ-on-a-chip systems, computational modelling, and advanced in vitro assays—to supplement and eventually reduce the reliance on traditional animal models.
Margin Expansion and Optimisation: The organisation will violently defend its operating margins through relentless price optimisation and the execution of its global footprint consolidation plan. By adopting a global business services model and centralising administrative processes, the enterprise aims to permanently reduce its SG&A cost base.

Key strengths

Unmatched End-to-End Portfolio: The enterprise operates as the absolute largest provider of outsourced drug discovery, non-clinical development, and regulated safety testing services worldwide. This allows clients to utilise a single, trusted partner from early target identification completely through to commercial manufacturing and lot release.
Irreplaceable Research Model Infrastructure: Operating an impenetrable global network of highly secure, pathogen-free barrier rooms and isolator facilities grants the enterprise an absolute monopolistic advantage in the reliable, global supply of over 140 strains of purpose-bred rodents.
Deep Scientific and Regulatory Expertise: The organisation employs approximately 2,400 science professionals with advanced degrees (Ph.D.s, D.V.M.s, and M.D.s). This unmatched intellectual capital ensures absolute data integrity and drastically reduces the risk of regulatory rejection for clients’ drug submissions.
Exceptional Cash Generation: The business model relies on highly fragmented contracts spanning thousands of clients, generating incredibly predictable, inflation-protected cash flows that fund massive share repurchases and strategic acquisitions without over-leveraging the balance sheet.

Key challenges and risks

Vulnerability to Biopharma Funding Cycles: The enterprise is highly exposed to the R&D budgets of small and mid-sized biotechnology companies. If macroeconomic conditions tighten, interest rates remain elevated, or venture capital funding dries up, these clients may abruptly cancel or delay massive clinical trials, leaving the enterprise exposed to sudden revenue drops.
Severe Supply Chain Disruptions for Research Models: The operations rely heavily on the continuous global supply of non-human primates (NHPs). Geopolitical export restrictions (particularly from China), legal investigations (such as the recent DOJ probe regarding Cambodian imports), or disease outbreaks can instantly choke off supply, causing severe pricing volatility and crippling the Safety Assessment division.
Intense Animal Rights Activism: Operating within the biomedical animal research sector exposes the enterprise to constant, severe negative attention, protests, and legal challenges from special interest groups. Activists frequently attempt to disrupt airline carriers from transporting animals or petition to have specific species declared endangered, which could fundamentally impair the business model.
Regulatory and Compliance Liabilities: Operating highly complex chemical treatment facilities, hazardous waste disposal, and cGMP biologic manufacturing plants exposes the enterprise to devastating legal and financial liabilities. The issuance of an FDA warning letter, a failure in data integrity, or a catastrophic contamination event within the animal breeding facilities could trigger massive financial losses and permanently destroy customer trust.

Conclusion and strategic outlook

Charles River Laboratories International, Inc. stands as an absolute titan of the global life sciences and pharmaceutical infrastructure landscape. Through decades of highly disciplined organic growth, aggressive strategic consolidation, and a unique focus on vertical integration across the non-clinical development spectrum, the enterprise has rapidly constructed a multi-billion-dollar, cash-generating fortress. By successfully passing inflationary costs down to a massive, diversified customer base while continuously modernising its scientific capabilities, the organisation continues to violently expand its operating margins and deliver immense returns to its shareholders.

Looking forward, the strategic outlook is exceptionally powerful. The transformational execution of the Board’s comprehensive strategic review, including the planned divestiture of non-core assets and the consolidation of its global footprint, will fundamentally optimise the corporate architecture. By deploying massive capital into advanced New Approach Methodologies, cell and gene therapy CDMO infrastructure, and the securing of its critical non-human primate supply chains, the organisation is perfectly positioned to capitalise on the exploding complexity of global drug development. Armed with unmatched scientific expertise, an expanding moat of regulatory accreditations, and a ruthless focus on operational excellence, the enterprise is primed to absolutely dominate the outsourced non-clinical research sector for decades to come.

FAQ section

What are the primary business segments of Charles River Laboratories? The organisation manages its operations primarily through three divisions: Discovery and Safety Assessment (DSA), Research Models and Services (RMS), and Manufacturing Solutions (Microbial and Biologics Solutions).

What is the strategic significance of the K.F. (Cambodia) Ltd. acquisition? In January 2026, the enterprise acquired assets of K.F. (Cambodia) Ltd. to vertically integrate the supply of non-human primates (NHPs) directly into its Safety Assessment operations. This critical move mitigates severe global supply chain constraints and ensures a reliable pipeline of research models for its clients.

How does the enterprise mitigate the risk of animal contamination? The organisation operates highly secure, pathogen-free barrier rooms and flexible film isolator facilities. It executes rigorous routine serology testing, quarantine procedures, and veterinary oversight to prevent the introduction of infectious agents that could distort scientific results or damage inventory.

What are New Approach Methodologies (NAMs)? NAMs are innovative in vitro, in silico, and computational modelling solutions designed to supplement, reduce, or eventually replace the use of traditional live animal models in biomedical research. The enterprise is heavily investing in these technologies to align with evolving global regulatory frameworks.

How did the company change its strategic direction in late 2025? Following a comprehensive review by the Board of Directors, the enterprise announced a strategy to divest non-core assets (representing roughly 7% of revenue), consolidate its global footprint by closing approximately 12 sites, and focus capital entirely on its core scientific portfolio and share repurchases.

What is the company’s approach to returning capital to shareholders? The enterprise does not pay a cash dividend. Instead, it is intensely committed to returning massive free cash flow to shareholders through aggressive open-market share repurchases, retiring $360.7 million of treasury stock during the 2025 fiscal year alone.

Official Site: https://www.criver.com/

Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.